While ICIs are usually not significantly effective for treatment of PDAC, administering ICIs—specifically anti–PD-1 or anti–PD-L1 therapies—during the post-RFA inflammatory window may block adaptive immune suppression and sustain cytotoxic T cell activity, improving outcomes in a classically immune-resistant tumor [66,70,71]. Here, CD274 is linked to neoplasm.